RxDoctor Payments Data

Miranda Coole, MD

Family Medicine · Louisville, KYNPI 1871740175

Payments from drug & device makers

$721in general payments, 2019–2025

Across 43 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$104
  • Novo Nordisk$92
  • Merck$82
  • AbbVie$75
  • Shield Therapeutics Inc$74
  • Pfizer$47
  • plus $246 from 12 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$104
Novo Nordisk6$92
Merck5$82
AbbVie(2 entities)5$75
Shield Therapeutics Inc2$74
Pfizer3$47
Alkermes, Inc.1$34
Cranial Technologies, Inc2$33
Sanofi Pasteur Inc.2$31
Gilead1$22
Bayer1$21
Hologic Sales And Service, LLC1$20
Exact Sciences1$17
VBI Vaccine (delaware) Inc.1$15
Lilly USA, LLC1$14
Cipher Pharmaceuticals US LLC1$14
Novartis1$13
Amgen1$13

How this compares

$721 in reported general payments places this provider in the 50th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$251
Medicare patients
19
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$48,850
JardianceEmpagliflozin42$33,777
JanuviaSitagliptin Phosphate29$30,718
EliquisApixaban13$21,407
AbrysvoRsv Vacc, Pref A And Pref B/Pf51$15,384
TrulicityDulaglutide15$14,109
ShingrixVaricella-Zoster Ge/As01b/Pf56$11,458
Diclofenac Sodium24$2,796
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,671
Atorvastatin Calcium203$1,834
Albuterol Sulfate HfaAlbuterol Sulfate47$1,333
Duloxetine Hcl15$840
Ventolin HfaAlbuterol Sulfate13$827
Amlodipine Besylate100$671
Levothyroxine Sodium54$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$92$48,85047 claims
PfizerEliquis, Abrysvo$47$36,79164 claims
MerckJanuvia$82$30,71829 claims
Lilly USA, LLCTrulicity$14$14,10915 claims
GSKShingrix$104$11,45856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →